ClinicalTrials.gg
CompletedNCT04447755E7080-G000-231Updated Oct 3, 2025Results posted

A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)

A Phase 2 interventional study of Lenvatinib in Relapsed or Refractory Solid Tumors, sponsored by Merck Sharp & Dohme LLC. Completed at 49 sites in 20 countries. Open to participants aged 2 Years to 21 Years. Per ClinicalTrials.gov, last updated 2025-10-03.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
127
Allocation
Non-randomized
Ages
2 Years to 21 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate the antitumor activity and safety of lenvatinib (MK-7902/E7080) in children, adolescents, and young adults with relapsed or refractory solid malignancies after administration. Participants were enrolled into Ewing sarcoma (EWS), rhabdomyosarcoma (RMS), high-grade glioma (HGG), diffuse midline glioma, medulloblastoma, ependymoma, and Other Solid Tumors Excluding Osteosarcoma, diffuse midline glioma, medulloblastoma, and ependymoma cohorts.

02

Conditions studied

  • Relapsed or Refractory Solid Tumors

Browse trials for

03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has or cytologically documented , or refractory pediatric solid excluding osteosarcoma
  • Has as defined by version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) for High Grade Glioma (HGG)
  • Has a performance status defined as follows: 1) Lansky Play Score ≥50 for participants up to and including 16 years of age 2) performance status (KPS) ≥50 for participants >16 years of age 3) Neurologic deficits in participants with primary central nervous system (CNS) tumors must have been stable for at least 7 days prior to study enrollment
  • Demonstrate adequate organ function
  • No clinical evidence of nephrotic syndrome.
  • Has adequate blood pressure (BP) control with or without antihypertensive medications
  • Has adequate cardiac function
  • Has adequate neurologic function
  • Participant must have fully recovered to , Version 5.0 (CTCAE v5.0) Grade ≤1 (except for alopecia, ototoxicity, and Grade ≤2 peripheral neuropathy) from the acute toxic effects of all prior anticancer therapy
  • Male participants must agree to use approved during the treatment period and for at least 7 days after the last dose of study intervention and refrain from donating sperm during this period
  • Female participants are not pregnant and not breastfeeding, and are not a woman of (WOCBP) or are a WOCBP who agrees to follow contraceptive guidance during the treatment period and for at least 30 days after the last dose of study intervention

Exclusion criteria

Exclusion Criteria:

  • Has had major surgery within 3 weeks prior to Cycle 1 Day 1 (C1D1)
  • Has gastrointestinal (GI) bleeding or active hemoptysis (bright red blood of at least half teaspoon) within 21 days prior to enrollment
  • Has CNS tumors with a history of symptomatic tumor hemorrhage
  • Has evidence of new intracranial hemorrhage of more than punctate size on MRI assessment obtained within 28 days prior to study enrollment
  • Has radiographic evidence of encasement or invasion of a major blood vessel or of intratumoral cavitation
  • Has evidence of untreated (exception: participants with primary CNS tumors and .
  • Has GI malabsorption, GI anastomosis, or any other condition that in the opinion of the investigator might affect the absorption of lenvatinib
  • Has preexisting ≥Grade 3 GI or non-GI fistula
  • Has any active infection requiring systemic therapy
  • Known to be (HIV) positive
  • Known active viral hepatitis (B or C) as demonstrated by positive serology. Testing for or is required at screening only when mandated by local health authority
  • Is currently participating and receiving study therapy, or has participated in a study of an agent and received study therapy or used an investigational device within 4 weeks of the date of allocation
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
  • Has known to any component of the investigational product (lenvatinib or ingredients)
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the stud
  • Has cardiovascular disease within 6 months from first dose of study intervention, including Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability
  • Has non-healing wound, tumor ulceration, unhealed or incompletely healed fracture, or a compound (open) bone fracture at the time of enrollment
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    Ewing Sarcoma

    Participants with Ewing sarcoma will receive lenvatinib 14 mg/m\^2 once daily (QD) orally until progressive disease or unacceptable toxicity.

    Drug: Lenvatinib

  • Experimental
    Rhabdomyosarcoma

    Participants with rhabdomyosarcoma will receive lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.

    Drug: Lenvatinib

  • Experimental
    High Grade Glioma

    Participants with high grade glioma will receive lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.

    Drug: Lenvatinib

  • Experimental
    Diffuse Midline Glioma

    Participants with diffuse midline glioma will receive lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.

    Drug: Lenvatinib

  • Experimental
    Medulloblastoma

    Participants with medulloblastoma will receive lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.

    Drug: Lenvatinib

  • Experimental
    Ependymoma

    Participants with ependymoma will receive lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.

    Drug: Lenvatinib

  • Experimental
    Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma

    Participants with other solid tumors will receive lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.

    Drug: Lenvatinib

Interventions

  • Lenvatinib capsules administered orally at 14 mg/m\^2 QD

    Also known as: MK-7902, E7080, LENVIMA

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) At Week 16 Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria (for High Grade Glioma [HGG] Only), by Investigator Assessment

    ORR at Week 16 was defined as the percentage of participants with a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters \[SOD\] of target lesions, taking as reference the baseline SOD) as assessed by the investigator per RECIST 1.1 at 16 Weeks. For participants with HGG, response was assessed according to RANO criteria whereby overall response is based on both radiographic response (CR: disappearance of all target lesions, PR: sum of products of diameters \[SPD\] decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information.

    Time frame: Up to 16 weeks

Secondary outcomes

  1. ORR Per RECIST 1.1 or RANO Criteria (for HGG Only), by Investigator Assessment

    ORR was defined as the percentage of participants with a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD) as assessed by the investigator per RECIST 1.1. For participants with HGG, response was assessed according to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information.

    Time frame: Up to approximately 21 months

  2. Progression Free Survival (PFS) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment

    PFS was defined as the time from the date of the first administration of study drug until the date of first documentation of progressive disease (PD) per RECIST 1.1 or RANO (for HGG) or death (whichever occurs first).

    Time frame: Up to approximately 21 months

  3. Best Overall Response (BOR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment

    BOR is defined as the participant's best confirmed response (CR or PR) over the treatment period as assessed by the investigator per RECIST 1.1 or RANO. As per RECIST 1.1, CR is defined as disappearance of all target lesions and PR is defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. For participants with HGG, response will be assessed according to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information.

    Time frame: Up to approximately 21 months

  4. Duration of Response (DOR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment

    DOR was defined as the time from the date of the first documented CR or PR to the date first documentation of progressive disease or death (whichever occurs first). As per RECIST 1.1, CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. For participants with HGG, response will be assessed according to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information.

    Time frame: Up to approximately 21 months

  5. Disease Control Rate (DCR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment

    DCR was defined as a BOR of CR or PR, or stable disease (SD). To be assigned a BOR of SD, the time from the first administration of study drug until the date of documented SD should be ≥7 weeks. As per RECIST 1.1, CR was defined as disappearance of all target lesions, PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For participants with HGG, response was assessed according to RANO criteria whereby overall response was based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value and SD: SPD \<50% decreased from baseline, but \<25% increased from nadir) and clinical performance status with steroid dose information.

    Time frame: Up to approximately 21 months

  6. Clinical Benefit Rate (CBR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment

    CBR was defined as a BOR of CR or PR, or durable SD (Duration of SD should be ≥23 weeks since the first dose of the study treatment. As per RECIST 1.1, CR was defined as disappearance of all target lesions, PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For participants with HGG, response is assessed according to RANO criteria whereby overall response was based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value and SD: SPD \<50% decreased from baseline, but \<25% increased from nadir) and clinical performance status with steroid dose information.

    Time frame: Up to approximately 21 months

  7. Number of Participants Who Experienced an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced at least one AE is reported.

    Time frame: Up to approximately 50 months

  8. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is reported.

    Time frame: Up to approximately 38 months

  9. Palatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Taste Category

    A hedonic Visual Analog Scale (VAS) was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the supplemental Statistical Analysis Plan (sSAP), all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the taste category is presented.

    Time frame: Cycle 1 Day 1 (cycle = 28 days)

  10. Palatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Appearance Category

    A hedonic VAS was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the appearance category is presented.

    Time frame: Cycle 1 Day 1 (cycle = 28 days)

  11. Palatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Smell Category

    A hedonic VAS was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the smell category is presented.

    Time frame: Cycle 1 Day 1 (cycle = 28 days)

  12. Palatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Mouth Feel Category

    A hedonic VAS was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the mouth feel category is presented.

    Time frame: Cycle 1 Day 1 (cycle = 28 days)

  13. Palatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Overall Acceptability Category

    A hedonic VAS was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the overall acceptability category is presented.

    Time frame: Cycle 1 Day 1 (cycle = 28 days)

  14. Area Under the Concentration-Time Curve of Lenvatinib at Steady State (AUCss)

    Blood samples were taken predose and at specified times postdose on Days 1-28 to determine the AUCss of Lenvatinib.

    Time frame: Cycle 1 Day 1 (0.5-4 and 6-10 hours post-dose), Cycle 1 Day 15 (pre-dose, 0.5-4, and 6-10 hours post-dose), and Cycle 2 Day 1 (pre-dose and 2-12 hours post-dose). A cycle is 28 days.

07

Results

Posted Oct 4, 2023

Participant flow

Participants were recruited to tumor cohorts of Ewing Sarcoma, Rhabdomyosarcoma, High Grade Glioma, and Other Solid Tumors Excluding Osteosarcoma. Enrollment to the protocol pre-specified tumor cohort of "Other Solid Tumors Excluding Osteosarcoma" was further expanded into categories of Diffuse midline glioma, Medulloblastoma, and Ependymoma.

Participant flow — Overall Study
MilestoneEwing SarcomaRhabdomyosarcomaHigh Grade GliomaDiffuse Midline GliomaMedulloblastomaEpendymomaOther Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma
Started917899966
Completed0000000
Not completed917899966
Withdrew: Death916898955
Withdrew: Withdrawal by parent/guardian0100000
Withdrew: Sponsor decision00001010
Withdrew: Lost to follow-up0000001

Outcome measures

PrimaryObjective Response Rate (ORR) At Week 16 Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria (for High Grade Glioma [HGG] Only), by Investigator Assessment

ORR at Week 16 was defined as the percentage of participants with a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters \[SOD\] of target lesions, taking as reference the baseline SOD) as assessed by the investigator per RECIST 1.1 at 16 Weeks. For participants with HGG, response was assessed according to RANO criteria whereby overall response is based on both radiographic response (CR: disappearance of all target lesions, PR: sum of products of diameters \[SPD\] decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information.

Time frame:
Up to 16 weeks
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) At Week 16 Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria (for High Grade Glioma [HGG] Only), by Investigator Assessment
Percentage of ParticipantsEwing SarcomaRhabdomyosarcomaHigh Grade GliomaDiffuse Midline GliomaMedulloblastomaEpendymomaOther Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma
Objective Response Rate (ORR) At Week 16 Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria (for High Grade Glioma [HGG] Only), by Investigator Assessment22.2 (2.8 to 60.0)11.8 (1.5 to 36.4)0.0 (0.0 to 45.9)0.0 (0.0 to 33.6)0.0 (0.0 to 33.6)0.0 (0.0 to 33.6)7.7 (2.5 to 17.0)
SecondaryORR Per RECIST 1.1 or RANO Criteria (for HGG Only), by Investigator Assessment

ORR was defined as the percentage of participants with a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD) as assessed by the investigator per RECIST 1.1. For participants with HGG, response was assessed according to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information.

Time frame:
Up to approximately 21 months
Reported as:
Number · Percentage of Participants
ORR Per RECIST 1.1 or RANO Criteria (for HGG Only), by Investigator Assessment
Percentage of ParticipantsEwing SarcomaRhabdomyosarcomaHigh Grade GliomaDiffuse Midline GliomaMedulloblastomaEpendymomaOther Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma
ORR Per RECIST 1.1 or RANO Criteria (for HGG Only), by Investigator Assessment22.2 (2.8 to 60.0)11.8 (1.5 to 36.4)0.0 (0.0 to 45.9)0.0 (0.0 to 33.6)0.0 (0.0 to 33.6)0.0 (0.0 to 33.6)7.7 (2.5 to 17.0)
SecondaryProgression Free Survival (PFS) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment

PFS was defined as the time from the date of the first administration of study drug until the date of first documentation of progressive disease (PD) per RECIST 1.1 or RANO (for HGG) or death (whichever occurs first).

Time frame:
Up to approximately 21 months
Reported as:
Median · Months
Progression Free Survival (PFS) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment
MonthsEwing SarcomaRhabdomyosarcomaHigh Grade GliomaDiffuse Midline GliomaMedulloblastomaEpendymomaOther Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma
Progression Free Survival (PFS) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment3.0 (0.3 to 9.3)2.6 (1.2 to 5.6)1.9 (1.4 to NA)1.8 (0.5 to 4.9)3.4 (0.5 to 8.5)2.5 (1.2 to 7.4)3.8 (3.2 to 5.7)
SecondaryBest Overall Response (BOR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment

BOR is defined as the participant's best confirmed response (CR or PR) over the treatment period as assessed by the investigator per RECIST 1.1 or RANO. As per RECIST 1.1, CR is defined as disappearance of all target lesions and PR is defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. For participants with HGG, response will be assessed according to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information.

Time frame:
Up to approximately 21 months
Reported as:
Number · Percentage of Participants
Best Overall Response (BOR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment
Percentage of ParticipantsEwing SarcomaRhabdomyosarcomaHigh Grade GliomaDiffuse Midline GliomaMedulloblastomaEpendymomaOther Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma
Best Overall Response (BOR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment22.2 (2.8 to 60.0)11.8 (1.5 to 36.4)0.0 (0.0 to 45.9)0.0 (0.0 to 33.6)0.0 (0.0 to 33.6)0.0 (0.0 to 33.6)7.7 (2.5 to 17.0)
SecondaryDuration of Response (DOR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment

DOR was defined as the time from the date of the first documented CR or PR to the date first documentation of progressive disease or death (whichever occurs first). As per RECIST 1.1, CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. For participants with HGG, response will be assessed according to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information.

Time frame:
Up to approximately 21 months
Reported as:
Median · Months
Duration of Response (DOR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment
MonthsEwing SarcomaRhabdomyosarcomaHigh Grade GliomaDiffuse Midline GliomaMedulloblastomaEpendymomaOther Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma
Duration of Response (DOR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator AssessmentNA (5.7 to NA)4.6 (3.7 to NA)————4.6 (3.7 to NA)
SecondaryDisease Control Rate (DCR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment

DCR was defined as a BOR of CR or PR, or stable disease (SD). To be assigned a BOR of SD, the time from the first administration of study drug until the date of documented SD should be ≥7 weeks. As per RECIST 1.1, CR was defined as disappearance of all target lesions, PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For participants with HGG, response was assessed according to RANO criteria whereby overall response was based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value and SD: SPD \<50% decreased from baseline, but \<25% increased from nadir) and clinical performance status with steroid dose information.

Time frame:
Up to approximately 21 months
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment
Percentage of ParticipantsEwing SarcomaRhabdomyosarcomaHigh Grade GliomaDiffuse Midline GliomaMedulloblastomaEpendymomaOther Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma
Disease Control Rate (DCR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment66.7 (29.9 to 92.5)52.9 (27.8 to 77.0)33.3 (4.3 to 77.7)22.2 (2.8 to 60.0)55.6 (21.2 to 86.3)55.6 (21.2 to 86.3)64.6 (51.8 to 76.1)
SecondaryClinical Benefit Rate (CBR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment

CBR was defined as a BOR of CR or PR, or durable SD (Duration of SD should be ≥23 weeks since the first dose of the study treatment. As per RECIST 1.1, CR was defined as disappearance of all target lesions, PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For participants with HGG, response is assessed according to RANO criteria whereby overall response was based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value and SD: SPD \<50% decreased from baseline, but \<25% increased from nadir) and clinical performance status with steroid dose information.

Time frame:
Up to approximately 21 months
Reported as:
Number · Percentage of Participants
Clinical Benefit Rate (CBR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment
Percentage of ParticipantsEwing SarcomaRhabdomyosarcomaHigh Grade GliomaDiffuse Midline GliomaMedulloblastomaEpendymomaOther Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma
Clinical Benefit Rate (CBR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment33.3 (7.5 to 70.1)29.4 (10.3 to 56.0)0.0 (0.0 to 45.9)11.1 (0.3 to 48.2)44.4 (13.7 to 78.8)33.3 (7.5 to 70.1)40.0 (28.0 to 52.9)
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced at least one AE is reported.

Time frame:
Up to approximately 50 months
Reported as:
Number · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsEwing SarcomaRhabdomyosarcomaHigh Grade GliomaDiffuse Midline GliomaMedulloblastomaEpendymomaOther Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma
Number of Participants Who Experienced an Adverse Event (AE)917899866
SecondaryNumber of Participants Who Discontinued Study Treatment Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is reported.

Time frame:
Up to approximately 38 months
Reported as:
Number · Participants
Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsEwing SarcomaRhabdomyosarcomaHigh Grade GliomaDiffuse Midline GliomaMedulloblastomaEpendymomaOther Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma
Number of Participants Who Discontinued Study Treatment Due to an AE1000126
SecondaryPalatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Taste Category

A hedonic Visual Analog Scale (VAS) was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the supplemental Statistical Analysis Plan (sSAP), all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the taste category is presented.

Time frame:
Cycle 1 Day 1 (cycle = 28 days)
Reported as:
Number · Participants
Palatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Taste Category
ParticipantsAll Tumor Types
Super Bad1
Really Bad0
Bad2
Maybe Good or Maybe Bad5
Good1
Really Good0
Super Good1
SecondaryPalatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Appearance Category

A hedonic VAS was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the appearance category is presented.

Time frame:
Cycle 1 Day 1 (cycle = 28 days)
Reported as:
Number · Participants
Palatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Appearance Category
ParticipantsAll Tumor Types
Super Bad0
Really Bad0
Bad1
Maybe Good or Maybe Bad5
Good2
Really Good0
Super Good2
SecondaryPalatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Smell Category

A hedonic VAS was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the smell category is presented.

Time frame:
Cycle 1 Day 1 (cycle = 28 days)
Reported as:
Number · Participants
Palatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Smell Category
ParticipantsAll Tumor Types
Super Bad0
Really Bad0
Bad0
Maybe Good or Maybe Bad8
Good1
Really Good0
Super Good1
SecondaryPalatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Mouth Feel Category

A hedonic VAS was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the mouth feel category is presented.

Time frame:
Cycle 1 Day 1 (cycle = 28 days)
Reported as:
Number · Participants
Palatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Mouth Feel Category
ParticipantsAll Tumor Types
Super Bad0
Really Bad1
Bad2
Maybe Good or Maybe Bad4
Good1
Really Good2
Super Good0
SecondaryPalatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Overall Acceptability Category

A hedonic VAS was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the overall acceptability category is presented.

Time frame:
Cycle 1 Day 1 (cycle = 28 days)
Reported as:
Number · Participants
Palatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Overall Acceptability Category
ParticipantsAll Tumor Types
Super Bad0
Really Bad1
Bad1
Maybe Good or Maybe Bad3
Good3
Really Good1
Super Good1
SecondaryArea Under the Concentration-Time Curve of Lenvatinib at Steady State (AUCss)

Blood samples were taken predose and at specified times postdose on Days 1-28 to determine the AUCss of Lenvatinib.

Time frame:
Cycle 1 Day 1 (0.5-4 and 6-10 hours post-dose), Cycle 1 Day 15 (pre-dose, 0.5-4, and 6-10 hours post-dose), and Cycle 2 Day 1 (pre-dose and 2-12 hours post-dose). A cycle is 28 days.
Reported as:
Geometric mean · ng*hr/ml
Area Under the Concentration-Time Curve of Lenvatinib at Steady State (AUCss)
ng*hr/mlEwing SarcomaRhabdomyosarcomaHigh Grade GliomaOther Solid Tumors Excluding Osteosarcoma
Area Under the Concentration-Time Curve of Lenvatinib at Steady State (AUCss)5896 ± 31.23915 ± 32.93660 ± 43.54990 ± 53.2

Adverse events

Collected over Up to approximately 50 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ewing Sarcoma9/9 (100%)4/9 (44.4%)9/9 (100%)
Rhabdomyosarcoma17/17 (100%)5/17 (29.4%)17/17 (100%)
High Grade Glioma8/8 (100%)6/8 (75%)6/8 (75%)
Diffuse Midline Glioma9/9 (100%)4/9 (44.4%)9/9 (100%)
Medulloblastoma8/9 (88.9%)4/9 (44.4%)9/9 (100%)
Ependymoma9/9 (100%)4/9 (44.4%)7/9 (77.8%)
Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma55/66 (83.3%)39/66 (59.1%)66/66 (100%)
Most frequent serious events
Showing 10 of 71
Most frequent serious events
EventEwing SarcomaRhabdomyosarcomaHigh Grade GliomaDiffuse Midline GliomaMedulloblastomaEpendymomaOther Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma
Pneumonia aspirationInfections and infestations0/90/170/82/90/90/91/66
PneumoniaInfections and infestations0/90/171/80/90/90/90/66
ArthritisMusculoskeletal and connective tissue disorders0/90/171/80/90/90/90/66
Muscular weaknessMusculoskeletal and connective tissue disorders0/90/171/80/90/90/90/66
HemiparesisNervous system disorders0/90/171/80/90/90/90/66
Intracranial pressure increasedNervous system disorders0/90/171/80/90/91/91/66
HypertensionVascular disorders0/90/171/80/91/90/91/66
Inappropriate antidiuretic hormone secretionEndocrine disorders0/90/170/80/91/90/90/66
Abdominal painGastrointestinal disorders1/90/170/80/91/90/93/66
ColitisGastrointestinal disorders1/90/170/80/90/90/90/66
Most frequent other events
Showing 10 of 198
Most frequent other events
EventEwing SarcomaRhabdomyosarcomaHigh Grade GliomaDiffuse Midline GliomaMedulloblastomaEpendymomaOther Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma
HypothyroidismEndocrine disorders7/98/174/87/97/95/945/66
DiarrhoeaGastrointestinal disorders5/96/170/80/94/93/922/66
FatigueGeneral disorders1/91/171/81/95/90/913/66
Decreased appetiteMetabolism and nutrition disorders5/97/172/83/93/91/918/66
HypertensionVascular disorders3/96/172/85/93/93/927/66
VomitingGastrointestinal disorders4/97/171/82/94/92/918/66
Urinary tract infectionInfections and infestations0/91/170/84/91/90/97/66
Platelet count decreasedInvestigations2/93/170/80/94/91/914/66
RashSkin and subcutaneous tissue disorders0/91/171/84/90/90/97/66
ProteinuriaRenal and urinary disorders2/95/170/83/92/91/928/66

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ewing SarcomaRhabdomyosarcomaHigh Grade GliomaDiffuse Midline GliomaMedulloblastomaEpendymomaOther Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and EpendymomaTotal
Mean14.8 ± 4.013.1 ± 4.714.0 ± 3.110.0 ± 5.213.2 ± 4.58.7 ± 5.713.1 ± 5.612.7 ± 5.3
Sex: Female, Male
Sex: Female, Male(Participants)Ewing SarcomaRhabdomyosarcomaHigh Grade GliomaDiffuse Midline GliomaMedulloblastomaEpendymomaOther Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and EpendymomaTotal
Female2748343260
Male71041653467
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ewing SarcomaRhabdomyosarcomaHigh Grade GliomaDiffuse Midline GliomaMedulloblastomaEpendymomaOther Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and EpendymomaTotal
Hispanic or Latino120010913
Not Hispanic or Latino51164264377
Unknown or Not Reported3425631437
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ewing SarcomaRhabdomyosarcomaHigh Grade GliomaDiffuse Midline GliomaMedulloblastomaEpendymomaOther Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and EpendymomaTotal
American Indian or Alaska Native10000023
Asian3213001322
Native Hawaiian or Other Pacific Islander01001002
Black or African American00000044
White31042273563
More than one race00000011
Unknown or Not Reported2434621132
08

Study locations

49 sites
  • Children's Hospital of Colorado ( Site 0110)
    Aurora, Colorado 80045, United States
  • Cleveland Clinic ( Site 0119)
    Cleveland, Ohio 44195, United States
  • Monroe Carell Jr. Children's Hospital at Vanderbilt ( Site 0102)
    Nashville, Tennessee 37232, United States
  • Mary Crowley Cancer Research Center ( Site 0107)
    Dallas, Texas 75230, United States
  • Hospital Universitario Austral ( Site 0126)
    Pilar, Buenos Aires B1629ODT, Argentina
  • Hospital de Niños Ricardo Gutiérrez ( Site 0125)
    Buenos Aires, Buenos Aires F.D. C1425EFD, Argentina
  • Sydney Children's Hospital ( Site 0801)
    Randwick, New South Wales 2031, Australia
  • Queensland Children s Hospital ( Site 0804)
    Brisbane, Queensland 4101, Australia
  • Royal Childrens Hospital Melbourne ( Site 0802)
    Parkville, Victoria 3052, Australia
  • Perth Children s Hospital ( Site 0803)
    Nedlands, Western Australia 6009, Australia
  • UZ Gent ( Site 0250)
    Ghent, Oost-Vlaanderen 9000, Belgium
  • Klinicki bolnicki centar Rijeka ( Site 0726)
    Rijeka, Primorje-Gorski Kotar County 51000, Croatia
  • Klinika za djecje bolesti Zagreb ( Site 0725)
    Zagreb, Zagreb County 10000, Croatia
  • Fakultni Nemocnice Brno Bohunice ( Site 0651)
    Brno, Brno-mesto 613 00, Czechia
  • Fakultni nemocnice v Motole ( Site 0650)
    Prague, 150 06, Czechia
  • Centre Leon-Berard ( Site 0326)
    Lyon, Auvergne 69008, France
  • Hopital La Timone ( Site 0328)
    Marseille, Bouches-du-Rhone 13005, France
  • Gustave Roussy ( Site 0327)
    Villejuif, Val-de-Marne 94800, France
  • Institut Curie ( Site 0325)
    Paris, 75005, France
  • Unidad Nacional de Oncologia Pediatrica ( Site 0176)
    Guatemala City, 01011, Guatemala
  • Medi-K Cayala ( Site 0177)
    Guatemala City, 01016, Guatemala
  • Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi OktatoKorhaz ( Site 0678)
    Miskolc, Borsod-Abauj Zemplen county 3526, Hungary
  • Semmelweis University ( Site 0675)
    Budapest, 1094, Hungary
  • Debreceni Egyetem Klinikai Kozpont ( Site 0677)
    Debrecen, 4032, Hungary
  • Chaim Sheba Medical Center ( Site 0500)
    Ramat Gan, 5265601, Israel
  • IRCCS Ospedale Pediatrico Bambino Gesu ( Site 0410)
    Rome, Roma 00165, Italy
  • A.O.Universitaria Meyer-Oncology & Haematology Unit ( Site 0400)
    Florence, Tuscany 50139, Italy
  • Istituto Giannina Gaslini ( Site 0411)
    Genova, 16147, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0401)
    Milan, 20133, Italy
  • Ospedale Infantile Regina Margherita ( Site 0412)
    Torino, 10126, Italy
  • Starship Childrens Hospital ( Site 0826)
    Auckland, 1023, New Zealand
  • Clinica Anglo Americana ( Site 0203)
    San Isidro, Lima region 15073, Peru
  • Dmitry Rogachev National Research Center ( Site 0550)
    Moscow, Moscow 117198, Russia
  • St.Petersburg State Medical Univ. n.a. acad. I.P.Pavlov ( Site 0554)
    Saint Petersburg, Sankt-Peterburg 197022, Russia
  • Clinical Research Center of specialized types medical care-Oncology ( Site 0553)
    Saint Petersburg, Sankt-Peterburg 197758, Russia
  • Institute for Oncology and Radiology of Serbia ( Site 0780)
    Belgrade, Beograd 11000, Serbia
  • Univerzitetska decja klinika ( Site 0782)
    Belgrade, Beograd 11000, Serbia
  • Wits Clinical Research ( Site 0579)
    Soweto, Gauteng 2013, South Africa
  • Cancercare Rondebosch Oncology ( Site 0575)
    Cape Town, Western Cape 7700, South Africa
  • Tygerberg Hospital ( Site 0578)
    Parow, Western Cape 7505, South Africa
  • Asan Medical Center ( Site 0876)
    Songpagu, Seoul 05505, South Korea
  • Seoul National University Hospital ( Site 0875)
    Seoul, 03080, South Korea
  • Hospital Universitario Sant Joan de Deu ( Site 0476)
    Esplugues de Llobregat, Barcelona 08950, Spain
  • Hospital Nino Jesus ( Site 0477)
    Madrid, 28009, Spain
  • Skanes Universitetssjukhus Lund. ( Site 0525)
    Lund, Skåne County 221 85, Sweden
  • Hacettepe Universitesi Tip Fakultesi ( Site 0603)
    Ankara, 06100, Turkey (Türkiye)
  • Istanbul Universitesi Onkoloji Enstitusu ( Site 0600)
    Istanbul, 34093, Turkey (Türkiye)
  • Ege Universitesi Tip Fakultesi ( Site 0601)
    Izmir, 35040, Turkey (Türkiye)
  • Dokuz Eylul Universitesi Arastirma Uygulama Hastanesi ( Site 0602)
    Izmir, 35330, Turkey (Türkiye)
09

References and documents

Publications

  • Gaspar N, Campbell-Hewson Q, Gallego Melcon S, Locatelli F, Venkatramani R, Hecker-Nolting S, Gambart M, Bautista F, Thebaud E, Aerts I, Morland B, Rossig C, Canete Nieto A, Longhi A, Lervat C, Entz-Werle N, Strauss SJ, Marec-Berard P, Okpara CE, He C, Dutta L, Casanova M. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆. ESMO Open. 2021 Oct;6(5):100250. doi: 10.1016/j.esmoop.2021.100250. Epub 2021 Sep 22. PubMed 34562750 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Sep 2022, 25 months.

Results were first posted in Oct 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2020
First posted
Jun 25, 2020
StartActual
Jul 30, 2020
Primary completionActual
Sep 16, 2022
CompletionActual
Feb 13, 2025
Results first posted
Oct 4, 2023
Last update
Oct 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04447755
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Jun 25, 2020
Start date
Jul 30, 2020
Primary completion
Sep 16, 2022
Completion
Feb 13, 2025
Results posted
Oct 4, 2023
Last update
Oct 3, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion